STAT+: FDA\u2019s rejection of Moderna threatens to stifle broader vaccine industry
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
The Food and Drug Administration\u2019s refusal to review Moderna\u2019s flu vaccine<\/a> this month has renewed fears that Trump administration policies could paralyze the vaccine industry, dissuading companies from developing new shots in the U.S. and leaving the country flat-footed in the event of future pandemics.\u00a0<\/p>\n \u201cI consider it an unprecedented action that really violates the basic principles of a data-driven regulatory agency and the fundamentals of public health, and it\u2019s that simple,\u201d said Gary Nabel, former head of the National Institutes of Health\u2019s Vaccine Research Center and chief scientist at Sanofi, who now runs a vaccine and cancer startup. \u201cIt\u2019s a destructive precedent that will undermine the future of vaccine development and the preeminence of American research.\u201d<\/p>\n Executives at large vaccine developers were already grappling with a litany of changes to vaccine policy. Under Robert F. Kennedy Jr., a longtime vaccine critic, the Department of Health and Human Services has unilaterally removed six shots from the childhood vaccination schedule<\/a>, canceled hundreds of millions of dollars in grants for mRNA shots<\/a>, and fired and replaced a key immunization advisory board<\/a>.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n